Karachi: Liven Pharma Limited has disclosed a series of share transactions involving its Executive Director, Kaashif Hussain Siddique, as per PSX Regulation 5.6.4. The transactions, dated January 6, 2026, reveal the sale of shares by Mr. Siddique across multiple transactions, cumulatively impacting his ownership in the company.

According to the details provided by Liven Pharma, Mr. Siddique executed a total of ten sell transactions on the Pakistan Stock Exchange (PSX). The sales included varying quantities of shares, with the largest single transaction involving 10,000 shares. The cumulative percentage of shares held by Mr. Siddique was affected by these transactions, resulting in a decline to 43.31% from an initial 43.36%.

The transactions were conducted in the ready market, with the share prices undisclosed for nine out of the ten transactions. However, the sale of 5,000 shares was executed at a rate of 52.02. According to information available from the Pakistan Stock Exchange (PSX), these transactions represent significant moves within the company’s shareholder structure.

The designated market category for these transactions was CDC, which is consistent with the standard practice for share dealings at PSX. The disclosure underscores the transparency required of substantial shareholders and key personnel in publicly traded companies, as mandated by local regulations.